News By Tag Industry News News By Place Country(s) Industry News
| Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors -Pipeline Insights, 2015By: DelveInsight The market is still dormant but pipeline is pitching and the market is expected to rise with the launch of several pipeline drugs in a few years. The “Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors -Pipeline Insights, 2015” report will help companies to optimize their portfolio by analyzing the market and creating effective counter-strategies for collaborations and licensing deals. In addition to this report on “Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors -Pipeline Insights, 2015”. Report also gives the information about: · • Therapeutic targets and their mechanism of action (MOA) according to latest R&D, pipeline products, technologies, clinical profiling, molecule type and stages of development. · • Information on collaborations and in-licensing & out-licensing deals. · • Information on 17 Pipeline drugs which includes 1 in PhaseIII, 1 Phase2/3, 6 Phase II, 3 PhaseI, 7 Pre-clinical and 2 in discovery along with 1 discontinued and 2 Inactive along with 21 active companies . · • Boston Biomedical Inc has developed Napabucasin (BBI608. Drug is under Phase III clinical trial. DelveInsight is offering the Report at a price of USD 1250 as a single user license, USD 2500 as a site license and USD 4000 as a Global/Enterprise License. About DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; End
|
|